ClinicalTrials.gg
CompletedNCT06553547Updated Aug 19, 2026

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

A Phase 2 interventional study of Tenapanor and Placebo in Irritable Bowel Syndrome With Constipation (IBS-C), sponsored by Ardelyx. Completed at 20 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Ardelyx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
9th of 11
72 · median 186
Started
2024
the only one that year
Phase 2
3 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 3 in phase 2, and was the 9th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.

Read the detailed description

This study consists of 2 week screening period in which subjects who have consented will be evaluated for eligibility per protocol requirements. During this 2 week screening period subjects will be given access to ediary in which they will be required to self report symptoms of IBS-C daily. Information in ediary will also be used to determine eligibility prior to enrollment.

During the 4 week RTP (Randomized treatment period), subjects will be randomized in in a ratio of 5:1 to receive tenapanor or matching placebo for 4 weeks. During the RTP, patients will continue recording daily assessments in the eDiary system as instructed and compliance with eDiary entries will be monitored. Patients will return for study visit every weeks (Visits 3-6) and will undergo safety assessments as per the protocol. At the end of this 4 week period, subjects will complete 2 week treatment free follow-up period and safety assessments per protocol will be conducted at the end of this 2 week period.

The study plans to enroll up to 6 cohorts of eligible patients sequentially, starting from Cohort 1 with 12 patients randomized in to receive tenapanor 2 mg BID or matching placebo for 4 weeks. Subsequent cohorts will assess increasing tenapanor doses, following a dose escalation order. The study will proceed to the next dosing cohort if the current cohort completes the 4-week RTP and does not meet any of the dose escalation stopping criteria pre-specified in the protocol.

03

Conditions studied

  • Irritable Bowel Syndrome With Constipation (IBS-C)

Keywords

  • IBS-C
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥6 and \<12 years old at the Screening visit (Visit 1)
  2. Confirmation of negative pregnancy test and use of appropriate (including abstinence) in female subjects that have experienced menarche and are of .
  3. Meet the Modified Diagnostic Rome IV criteria for child/adolescent diagnosis of IBS-C
  4. Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  5. Meet the entry criteria assessed during the 2-week Screening period
  6. Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  7. Patient must provide verbal assent and the parent/guardian/LAR must provide written before the initiation of any study-specific procedures

Exclusion criteria

Exclusion Criteria:

  1. Functional diarrhea as defined by Modified Rome IV child/adolescent criteria
  2. IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Modified Rome IV child/adolescent criteria
  3. History of non-retentive fecal incontinence;
  4. Required manual disimpaction any time prior to randomization (after consent)
  5. Currently has both unexplained and alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process.
  6. Patient has any of the following conditions:

    1. Celiac disease, or positive serological test for celiac disease and the condition has not been ruled out by endoscopic ;
    2. Cystic fibrosis;
    3. Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to the Screening Visit;
    4. Down's syndrome or any other chromosomal disorder;
    5. Active anal fissure (Note: History of anal fissure is not an exclusion);
    6. Anatomic malformations (eg, imperforate anus, anal stenosis, anterior displaced anus);
    7. Intestinal nerve or muscle disorders (eg, Hirschprung disease, visceral myopathies, visceral neuropathies);
    8. Neuropathic conditions (eg, spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma);
    9. Lead toxicity, hypercalcemia;
    10. Neurodevelopmental disabilities
    11. Inflammatory bowel disease
    12. Childhood functional abdominal pain syndrome
    13. Childhood functional abdominal pain
    14. Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    15. Lactose intolerance that is associated with abdominal pain or discomfort and could confound the assessments in this study
    16. History of cancer other than treated basal cell carcinoma of the skin;
    17. History of diabetic neuropathy.
  7. Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.
  8. Patient has had surgery that meets any of the following criteria:

    1. Surgery to remove a segment of the GI tract at any time before the Screening Visit;
    2. Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    3. An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    4. Other major surgery during the 30 days before the Screening Visit
  9. History of alcohol or substance abuse
  10. Participation in other clinical trials within 1 month prior to Screening
  11. Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
  12. If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Tenapanor Cohort 1

    Tenapanor 2 mg BID

    Drug: Tenapanor

  • Experimental
    Tenapanor Cohort 2

    Tenapanor 5 mg BID

    Drug: Tenapanor

  • Experimental
    Tenapanor Cohort 3

    Tenapanor 10 mg BID

    Drug: Tenapanor

  • Experimental
    Tenapanor Cohort 4

    Tenapanor 15 mg BID

    Drug: Tenapanor

  • Experimental
    Tenapanor Cohort 5

    Tenapanor 20 mg BID

    Drug: Tenapanor

  • Experimental
    Tenapanor Cohort 6

    Tenapanor 25 mg BID

    Drug: Tenapanor

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Tenapanor 5 mg/mL solution

    Also known as: IBSRELA

  • DrugPlacebo

    Matching Placebo solution

06

What researchers measure

Primary outcomes

  1. Average weekly SBM (week 4)

    Change from baseline in average weekly SBM frequency in Week 4

    Time frame: 4 weeks

Secondary outcomes

  1. Average weekly SBM (weeks 1, 2 and 3)

    Change from baseline in average weekly SBM frequency in Week 1, Week 2, and Week 3

    Time frame: 3 weeks

  2. SBM Response

    Weekly ≥3 SBM response: achieving an average weekly SBM frequency ≥3 for a given week

    Time frame: 6 weeks

  3. Stool consistency

    Percent change from baseline in average weekly stool consistency score in each week Scale Range: 1. one (1)= Rabbit droppings: separate hard lumps, like nuts (hard to pass) 2. seven (7) for Gravy: watery, no solids pieces, entirely liquid"

    Time frame: 6 weeks

  4. Abdominal Pain Score

    Percent change from baseline in average weekly abdominal pain score in each week Scale Range: zero (0) = no pain and ten (10)= very severe abdominal pain

    Time frame: 6 weeks

  5. Rescue medication

    Overall use of rescue medication

    Time frame: 6 weeks

07

Study locations

20 sites
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72205, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Waterway Research & Associates Corp.
    Miami, Florida 33155, United States
  • Valencia Medical and Research Center
    Miami, Florida 33165, United States
  • Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
    Orlando, Florida 32806, United States
  • Florida Pharmaceutical Research and Associates, Inc.
    South Miami, Florida 33143, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Mankato Clinic Children's Health Center
    Mankato, Minnesota 56001, United States
  • Boys Town National Research Hospital
    Boys Town, Nebraska 68010, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Wilmington Health
    Wilmington, North Carolina 28401, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Prisma Health Children's Hospital
    Greenville, South Carolina 29615, United States
  • Maspons Pediatric Gastro
    El Paso, Texas 79902, United States
  • Proactive El Paso, LLC
    El Paso, Texas 79902, United States
  • Texas Digestive Specialists
    Harlingen, Texas 78550, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Pioneer Research Solutions Inc
    Sugar Land, Texas 77479, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • University Physicians and Surgeons, Inc
    Huntington, West Virginia 25701, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2026, 23 months.

Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 23 months is above that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 14, 2024
StartActual
Jul 24, 2024
Primary completionActual
Jul 7, 2026
CompletionActual
Jul 7, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06553547
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Jul 24, 2024
Primary completion
Jul 7, 2026
Completion
Jul 7, 2026
Last update
Aug 19, 2026

Study contacts

Jocelyn Tabora
study director · Ardelyx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion